Aurinia Pharmaceuticals: Promising Growth and Stability with Lupkynis and Pipeline Advancements

Stacy Ku, an analyst from TD Cowen, maintained the Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report). The associated price target remains the same with $11.00.

Stacy Ku has given her Buy rating due to a combination of factors that highlight the potential growth and stability of Aurinia Pharmaceuticals. The company has shown promising sales figures for its drug Lupkynis, with Q1 sales aligning with market expectations and a positive outlook for 2025. Management’s forecast of $240-250 million in sales by 2025 reflects a 13% year-over-year growth, which is supported by steady patient additions and high conversion rates.
Furthermore, the ongoing progress in Aurinia’s pipeline, particularly with AUR200, adds to the company’s growth prospects. Despite the company’s standalone status, which might limit strategic synergies, the positive feedback from key opinion leaders and consultants about Lupkynis’s potential in treating lupus nephritis indicates a strong market position. The anticipated updates in ACR guidelines could further enhance the drug’s adoption, making it a significant player in the treatment landscape.